Label: GALBRIELA- norethindrone and ethinyl estradiol and ferrous fumarate kit

  • NDC Code(s): 70700-306-84, 70700-306-85
  • Packager: Xiromed, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated August 31, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use GALBRIELA safely and effectively. See full prescribing information for GALBRIELA.   GALBRIELATM (norethindrone and ethinyl ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4) and Warnings & Precautions (5.1)].

    Close
  • 1 INDICATIONS AND USAGE
    Galbriela (norethindrone and ethinyl estradiol chewable tablet and ferrous fumarate chewable tablet) is indicated for use by women to prevent pregnancy. The efficacy of Galbriela in women with a ...
  • 2 DOSAGE AND ADMINISTRATION
    2.1 How to Take Galbriela - To achieve maximum contraceptive effectiveness, Galbriela must be taken exactly as directed. Chew and swallow one tablet without water at the same time every day ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Galbriela is available in blister packs. Each blister pack (28 tablets) contains in the following order: 24 dark yellow, round tablets (active) debossed with 259 on one side and other side ...
  • 4 CONTRAINDICATIONS
    Galbriela is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thrombotic and Other Vascular Events - Stop norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) if an arterial or deep venous thrombotic (VTE ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and smoking [see Boxed Warning, and Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    No drug-drug interaction studies were conducted with norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable). 7.1 Changes in Contraceptive Effectiveness ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - There is no use for contraception in pregnancy; therefore, norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) should be ...
  • 10 OVERDOSAGE
    There have been no reports of serious ill effects from overdose of oral contraceptives including ingestion by children. Overdosage may cause nausea, and withdrawal bleeding may occur in females ...
  • 11 DESCRIPTION
    Galbriela (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) provides an oral contraceptive regimen consisting of 24 tablets that contain the active ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - COCs lower the risk of becoming pregnant primarily by suppressing ovulation. 12.2 Pharmacodynamics - No specific pharmacodynamic studies were conducted with ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - [See Warnings and Precautions (5.2, 5.3).]
  • 14 CLINICAL STUDIES
    14.1 Oral Contraceptive Clinical Trial - In a one-year (thirteen 28-day cycles) multicenter, open-label clinical trial, 1,677 women 18 to 46 years of age were studied to assess the safety and ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - Galbriela is available in cartons of 3 pouches (NDC 70700-306-85); each pouch (NDC 70700-306-84) contains a blister pack of 28 tablets. Each blister pack contains 24 dark ...
  • 17 PATIENT COUNSELING INFORMATION
    See FDA-Approved Patient Labeling - Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke ...
  • FDA-Approved Patient Labeling
    Guide for Using Galbriela - WARNING TO WOMEN WHO SMOKE - Do not use Galbriela if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side ...
  • PRINCIPAL DISPLAY PANEL - 0.8 mg /0.025 mg
    NDC 70700-306-85 - GalbrielaTM - (Norethindrone and Ethinyl Estradiol Tablets (Chewable) and Ferrous Fumarate Tablets (Chewable)) 0.8 mg /0.025 mg - Rx only
  • INGREDIENTS AND APPEARANCE
    Product Information